India Tightens Watch on GLP-1 Drugs Amid Safety and Misuse Concerns
India's drug regulators are intensifying GLP-1 oversight ahead of semaglutide's patent expiry. The Drug Controller General audited 49 entities and issued notices to violators.
#generics
3 stories
India Semaglutide Prices Expected to Drop 70% as 50+ Generics Enter Market
Following Novo Nordisk's patent expiry on March 20, more than 50 generic semaglutide versions are anticipated in India, dramatically expanding GLP-1 access.
Biocon Skips India's Crowded Generic Semaglutide Market, Eyes Global Expansion
Biocon's incoming CEO said the company will prioritize Canada, Brazil, and the Middle East instead of India's saturated GLP-1 market with 40+ generic entrants.